Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
multi-strain probiotics
- Development stage
- Unknown
- Lead developer
- University of Calgary
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Enteral
01
Overview
This multi-strain probiotic intervention, studied by researchers at the University of Calgary, is a combination of *Bifidobacterium* and *Lacticaseibacillus* species designed to prevent necrotizing enterocolitis (NEC) in very preterm infants (born at less than 32 weeks gestation). The therapy works by colonizing the neonatal gut to establish a healthy intestinal microbiota, thereby reducing inflammation and preventing the translocation of pathogenic bacteria associated with NEC. It is currently being evaluated in a stepped-wedge cluster randomized trial to assess its efficacy in reducing NEC incidence and improving feeding tolerance in extremely low-birth-weight (ELBW) infants. The formulation aims to sustain beneficial bacterial populations and help infants achieve full enteral feeds sooner.
- Other names
- Bifidobacterium + Lacticaseibacillusmulti-strain probiotics for NEC
Beyond the preview
Go deeper on multi-strain probiotics.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on multi-strain probiotics.